The Anti-KIR2D antibody recognizes the killer immunoglobulin-like receptor (KIR) 2D subtype on human and non-human primate cells. It recognizes all KIRs bearing two extracellular Ig-like domains, and also both activating and inhibitory KIR isoforms (KIR2DS and KIR2DL, respectively). KIRs are expressed on CD56dimCD16+ natural killer (NK) cells and a subset of CD8+ T cells. KIRs contribute to the regulation of NK cell-mediated cytotoxicity. They are monomeric receptors possessing high allelic polymorphism with either two or three Ig-like extracellular domains (KIR2D or KIR3D, respectively). According to the length of their cytoplasmic tail, KIRs can be subdivided in long-tailed inhibitory KIRs (KIR2DL or KIR3DL) and short-tailed activating KIRs (KIR2DS or KIR3DS).
Cross reactivity
This antibody has been tested to cross-react with
Rhesus monkey (Macaca mulatta)
原厂资料:
The Anti-KIR2D antibody recognizes the killer immunoglobulin-like receptor (KIR) 2D subtype on human and non-human primate cells. It recognizes all KIRs bearing two extracellular Ig-like domains, and also both activating and inhibitory KIR isoforms (KIR2DS and KIR2DL, respectively). KIRs are expressed on CD56dimCD16+ natural killer (NK) cells and a subset of CD8+ T cells. KIRs contribute to the regulation of NK cell-mediated cytotoxicity. They are monomeric receptors possessing high allelic polymorphism with either two or three Ig-like extracellular domains (KIR2D or KIR3D, respectively). According to the length of their cytoplasmic tail, KIRs can be subdivided in long-tailed inhibitory KIRs (KIR2DL or KIR3DL) and short-tailed activating KIRs (KIR2DS or KIR3DS).